Co-creation and joint out-licensing with biotech ventures through DDAIF Innovation Bridge

「This is a model that combines DDAIF with financial support to help biotech ventures maximize the value of their drug discovery pipelines. In the first phase, DDAIF is used to strengthen mechanistic hypotheses relating to a biotech venture's pipeline, thereby reducing research uncertainty, improving the probability of success and advancing research progress, while providing financial support, including equity investments, for validation and repeat experiments. In the second phase, we support the review of the pipeline and the redesign of new drug discovery strategies in light of the research environment and competitive landscape.」